Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18713)	4/6/1998 5:46:00 PM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

THe orig phen/fen numbers of people having problems were grossly overstated. there were "quiet" updates such as in the WSJ that showed that the orig percentages of people having problems were overstated. The cancer prevention study will help lgnd if it can be shown that high risk patients have an even better chance of staying healthy if they take Targretin over Tamoxifen or Targretin along with Tamox. I demand that the FDA do this study. NOW!